Document:

EX-10.12

 Exhibit 10.12 

NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”) OR THE SECURITIES LAWS OF ANY STATE. SUBJECT TO SECTION 6 BELOW, AND EXCEPT IN COMPLIANCE WITH RULE 144 UNDER THE ACT, NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION
OF COUNSEL FOR HOLDER, SATISFACTORY TO COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECEIPT OF A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION. 

WARRANT TO PURCHASE [             ] SHARES OF SERIES 3 PREFERRED STOCK

 [            ], 2014 

THIS CERTIFIES THAT, for value received, [WARRANT HOLDER] (“Holder”) is entitled to
subscribe for and purchase up to such number of fully paid and nonassessable shares of Series 3 Preferred Stock of Cardiva Medical, Inc., a Delaware corporation (“Company”), as is equal to the Warrant Share Amount (as hereinafter defined)
at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Preferred Stock” shall mean Company’s presently authorized Series 3 Preferred
Stock, $0.001 par value per share, and any stock into which such Series 3 Preferred Stock may hereafter be converted or exchanged, and the term “Warrant Shares” shall mean the shares of Preferred Stock which Holder may acquire pursuant to
this Warrant and any other shares of stock into which such shares of Preferred Stock may hereafter be converted or exchanged. 
 1. Warrant Share Amount
and Warrant Price. The “Warrant Share Amount” means such whole number (with any fractions rounded up) as is equal to the quotient of(a) the product of (i) the original principal amount of the Term Loan A (as defined in the Loan
and Security Agreement dated as of July 24, 2014, among General Electric Capital Corporation, as Agent, the Lenders (as defined therein), and Company, as Borrower and the other entities or persons from time to time party thereto as Guarantors
(as amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”)) made by Holder or its affiliates pursuant to the terms of the Loan Agreement, multiplied by (ii) one and two tenths percent
(1.2 %), divided by (b) the Warrant Price. The “Warrant Price” shall be one and 25/100 dollars ($1.25) per share, subject to adjustment as provided in Section 7 below. 

2. Conditions to Exercise. The purchase right represented by this Warrant may be exercised at any time, or from time to time, in whole or in part during
the term commencing on the date hereof and ending at 5:00 P.M. (New York City time) on the tenth anniversary of the date of this Warrant (the “Expiration Date”). 

3. Method of Exercise or Conversion; Payment; Issuance of Shares: Issuance of New Warrant. 

(a) Cash Exercise. Subject to Section 2 hereof, the purchase right represented by this Warrant may be exercised by Holder hereof,
in whole or in part, by the surrender of the original of this Warrant (together with a duly executed Notice of Exercise in substantially the form attached hereto) at the principal office of Company (as set forth in Section 19 below) and by
payment to Company, by certified or bank check, or wire transfer of immediately available funds, of an amount equal to the then applicable Warrant Price per share multiplied by the number of Warrant Shares then being purchased. In the event of any
exercise of the rights represented by this Warrant, certificates for the shares of stock so purchased shall be in the name of, and delivered to, Holder hereof, or as such Holder may direct (subject to the terms of transfer contained herein and upon
payment by such Holder hereof of any applicable transfer taxes). Such delivery shall be made within 30 days after exercise of this Warrant and at Company’s expense and, unless this Warrant has been fully exercised or expired, a new Warrant
having terms and conditions substantially identical to this Warrant and representing the portion of the Warrant Shares, if any, with respect to which this Warrant shall not have been exercised, shall also be issued to Holder hereof within 30 days
after exercise of this Warrant. 

 (b) Conversion. In lieu of exercising this Warrant as specified in Section 3(a), Holder
may from time to time convert this Warrant, in whole or in part, into Warrant Shares by surrender of the original of this Warrant (together with a duly executed Notice of Exercise in substantially the form attached hereto) at the principal office of
Company, in which event Company shall issue to Holder the number of Warrant Shares computed using the following formula: 
  

			
	 X=Y
	  	(A-B)
		  	 A

 Where: 

X = the number of Warrant Shares to be issued to Holder. 

Y = the number of Warrant Shares with respect to which this Warrant is being exercised (including any Warrant Shares surrendered to the Company
in payment of the aggregate Warrant Price) (at the date of such calculation). 
 A = the Fair Market Value of one share of Company’s
Preferred Stock (at the date of such calculation). 
 B = Warrant Price (as adjusted to the date of such calculation). 

(c) Fair Market Value. For purposes of this Section 3, Fair Market Value of one share of Company’s Preferred Stock shall mean:

 (i) In the event of an exercise in connection with the initial underwritten public offering of shares of common stock of the Company
(“Common Stock”) pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Act”), the offering price at which the underwriters initially sell Common Stock to the public multiplied by the
number of shares of Common Stock into which each share of Preferred Stock is then convertible; or 
 (ii) The average of the closing bid and
asked prices of Common Stock quoted in the Over-The-Counter Market Summary, or the last reported sale price quoted on the Nasdaq Stock Market or on any other exchange on
which the Common Stock is listed, whichever is applicable, as published in the Eastern Edition of the Wall Street Journal for the three (3) trading days prior to the date of determination of Fair Market Value, multiplied by the number of
shares of Common Stock into which each share of Preferred Stock is then convertible; or 
 (iii) In the event of an exercise in connection
with a merger, acquisition or other consolidation in which Company is not the surviving entity, the value to be received per share of Preferred Stock by all holders of the Preferred Stock in such transaction as determined in the reasonable good
faith judgment of Company’s Board of Directors; or 
 (iv) In any other instance, the value as determined in the reasonable good faith
judgment of Company’s Board of Directors. 
 In the event of Section 3(c)(iii) or 3(c)(iv) above, Company’s Board of Directors
shall prepare a certificate, to be signed by an authorized officer of Company, setting forth in reasonable detail the basis for and method of determination of the per share Fair Market Value of the Preferred Stock. The Board of Directors will also
certify to Holder that, in the event of Section 3(c)(iii) above, this per share Fair Market Value is equal to the value to be received per share of Preferred Stock by all holders of the Preferred Stock in such transaction and, in the event of
Section 3(c)(iv) above, the Board of Directors has not made any other determinations of the Fair Market Value for any other holders of the Company’s Preferred Stock that are inconsistent with the determination for purposes of this Warrant
and will not make such an inconsistent determination thereafter in the absence of any events that later materially affect the value of the Company’s Preferred Stock. Such certifications must be made to Holder, in the event of
Section 3(c)(iii) above, at least ten (10) business days prior to the proposed effective date of the merger, acquisition or other consolidation, and in the event of Section 3(c)(iv), promptly after exercise of this Warrant. 

  
 2 

 (d) Automatic Exercise. To the extent this Warrant is not previously exercised, it
shall be deemed to have been automatically converted in accordance with Sections 3(b) and 3(c) hereof (even if not surrendered) as of immediately before its expiration, involuntary termination or cancellation (including, without limitation, pursuant
to Section 3(e)(ii)) if the then-Fair Market Value of a Warrant Share exceeds the then-Warrant Price, unless Holder notifies Company in writing to the contrary prior to such automatic exercise. 

(e) Treatment of Warrant Upon Acquisition of Company. 

(i) Certain Definitions. For the purpose of this Warrant: “Acquisition” means any sale, license, assignment, or other
disposition of all or substantially all of the assets of Company, or any reorganization, consolidation, or merger of Company, or sale of outstanding Company securities by holders thereof, where the holders of Company’s securities as of
immediately before the transaction beneficially own less than a majority of the outstanding voting securities of the successor or surviving entity as of immediately after the transaction. For purposes of this Section 3(e), “Affiliate”
shall mean any person or entity that owns or controls directly or indirectly ten percent (10%) or more of the voting capital stock of Company, any person or entity that controls or is controlled by or is under common control with such persons or
entities, and each of such person’s or entity’s officers, directors, joint venturers or partners, as applicable. Company shall provide Holder with written notice of any proposed Acquisition not later than ten (10) business days prior
to the closing thereof setting forth the material terms and conditions thereof, and shall provide Holder with copies of the draft transaction agreements and other documents in connection therewith and with such other information respecting such
proposed Acquisition as may reasonably be requested by Holder. 
 (ii) Acquisition for Cash. Holder agrees that, in the event of an
Acquisition in which the sole consideration is cash or Marketable Securities (as hereinafter defined), this Warrant shall be automatically exercised (or terminate) as provided in Section 3(d) on and as of the closing of such Acquisition to the
extent not previously exercised. For purposes of this Section 3(e), “Marketable Securities” shall mean securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of
Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act;
(ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded on a nationally
recognized securities exchange, inter-dealer quotation system or over-the-counter market, and (iii) following the closing of such Acquisition, Holder would not be
restricted from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise or convert this Warrant in full on or
prior to the closing pf such Acquisition, except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of
such Acquisition. 
 (iii) Asset Sale. In the event of an Acquisition that is an arm’s length sale of all or substantially all of
Company’s assets (and only its assets) to a third party that is not an Affiliate of Company (a “True Asset Sale”), Holder may either (a) exercise its conversion or purchase right under this Warrant and such exercise will be
deemed effective immediately prior to the consummation of such Acquisition, or (b) permit the Warrant to continue until the Expiration Date if Company continues as a going concern following the closing of any such True Asset Sale. 

(iv) Assumption of Warrant. Upon the closing of any Acquisition other than as particularly described in Section 3(e)(ii) or
3(e)(iii) above, Company shall, unless Holder requests otherwise, cause the surviving or successor entity to assume this Warrant and the obligations of Company hereunder, and this Warrant shall, from and after such closing, be exercisable for the
same class, number and kind of securities, cash and other property as would have been paid for or in respect of the shares issuable (as of immediately prior to such closing) upon exercise in full hereof as if such shares had been issued and
outstanding on and as of such closing, at an aggregate Warrant Price equal to the aggregate Warrant Price in effect as of immediately prior to such closing; and subject to further adjustment thereafter from time to time in accordance with the
provisions of this Warrant. 

  
 3 

 4. Representations and Warranties of Holder and Company. 

(a) Representations and Warranties by Holder. Holder represents and warrants to Company as of the date hereof with respect to this
Warrant as follows: 
 (i) Evaluation. Holder has substantial experience in evaluating and investing in private placement transactions
of securities of companies similar to Company so that Holder is capable of evaluating the merits and risks of its investment in Company and has the capacity to protect its interests. 

(ii) Resale. Except for transfers to an affiliate of Holder, Holder is acquiring this Warrant and the Warrant Shares issuable upon
exercise of this Warrant (collectively the “Securities”) for investment for its own account and not with a view to, or for resale in connection with, any distribution thereof. Holder understands that the Securities have not been registered
under the Act by reason of a specific exemption from the registration provisions of the Act which depends upon, among other things, the bona fide nature of the investment intent as expressed herein. 

(iii) Rule 144. Holder acknowledges that the Securities must be held indefinitely unless subsequently registered under the Act or an
exemption from such registration is available. Holder is aware of the provisions of Rule 144 promulgated under the Act. 
 (iv) Accredited
Investor. Holder is an “accredited investor’’ within the meaning of Regulation D promulgated under the Act. 
 (v)
Opportunity To Discuss. Holder has had an opportunity to discuss Company’s business, management and financial affairs with its management and an opportunity to review Company’s facilities. Holder understands that such discussions,
as well as the written information issued by Company, were intended to describe the aspects of Company’s business and prospects which Company believes to be material but were not necessarily a thorough or exhaustive description. 

(b) Representations and Warranties by Company. Company hereby represents and warrants to Holder that the statements in the following
paragraphs of this Section 4(b) are true and correct as of the date hereof. 
 (i) Corporate Organization and Authority. Company
(a) is a corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization, (b) has the corporate power and authority to own and operate its properties and to carry on its business as
now conducted and as proposed to be conducted; and (c) is qualified as a foreign corporation in all jurisdictions where the failure to be so qualified could reasonably be expected to have a material adverse effect on the Company’s
financial condition or business as currently conducted. 
 (ii) Corporate Power. Company has all requisite legal and corporate power
and authority to execute, issue and deliver this Warrant, to issue the Warrant Shares issuable upon exercise or conversion of this Warrant, and to carry out and perform its obligations under this Warrant. 

(iii) Authorization; Enforceability. All corporate action on the part of Company, its officers, directors and shareholders necessary for
the authorization, execution, delivery and performance of its obligations under this Warrant and for the authorization, issuance and delivery of this Warrant and the Warrant Shares issuable upon exercise of this Warrant has been taken and this
Warrant constitutes the legally binding and valid obligation of Company enforceable in accordance with its terms except as limited by laws of general application relating to bankruptcy, insolvency and the relief of debtors and as limited by rules of
law governing specific performance, injunctive relief or other equitable remedies and by general principles of equity. 

  
 4 

 (iv) Valid Issuance of Warrant and Warrant Shares. This Warrant has been validly
issued and is free of restrictions on transfer other than restrictions on transfer set forth herein, in the Rights Agreement and under applicable state and federal securities laws. The Warrant Shares issuable upon exercise or conversion of this
Warrant, when issued, sold and delivered in accordance with the terms of this Warrant for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable, and will be free of restrictions on transfer other than
restrictions on transfer under this Warrant, under the Rights Agreement and under applicable state and federal securities laws. Subject to applicable restrictions on transfer, the issuance and delivery of this Warrant and the Warrant Shares issuable
upon exercise or conversion of this Warrant are not subject to any preemptive or other similar rights or any liens or encumbrances not previously waived except as specifically set forth in Company’s Certificate of Incorporation
(“Certificate of Incorporation”) or this Warrant. The offer, sale and issuance of the Warrant Shares, as contemplated by this Warrant, are exempt from the prospectus and registration requirements of applicable United States federal and
state security laws, and neither Company nor any authorized agent acting on its behalf has taken or will take any action hereafter that would cause the loss of such exemption. 

(v) No Conflict. The execution, delivery, and performance of this Warrant will not result in (a) any violation of, be in conflict
with, or constitute a default under, with or without the passage of time or the giving of notice (1) any provision of Company’s Certificate of Incorporation or by-laws; (2) any provision of any
judgment, decree, or order to which Company is a party, by which it is bound, or to which any of its material assets are subject; (3) any contract, obligation, or commitment to which Company is a party or by which it is bound; or (4) any
statute, rule, or governmental regulation applicable to Company, or (b) the creation of any lien, charge or encumbrance upon any assets of Company. 

(vi) Capitalization. The capitalization table of Company attached hereto as Annex A is complete and accurate as of the date hereof
(after giving effect to the issuance of this Warrant) and reflects (a) all outstanding capital stock of Company and (b) all outstanding warrants, options, conversion privileges, preemptive rights or other rights or agreements to purchase
or otherwise acquire or issue any equity securities or convertible securities of Company. Company has reserved [_____] shares of Common Stock for issuance upon conversion of the Preferred Stock. 

(vii) Warrant Price. The Warrant Price is no greater than the lowest price at which Company has issued Series 3 Preferred Stock to an
unrelated third party for cash proceeds in an arm’s length transaction. 
 5. Legends. 

(a) Legend. Each certificate representing the Warrant Shares shall be endorsed with substantially the following legend: 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) OR THE SECURITIES LAWS OF ANY STATE AND MAY
NOT BE TRANSFERRED (UNLESS SUCH TRANSFER IS TO AN AFFILIATE OF HOLDER) UNLESS COVERED BY AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, A “NO ACTION” LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION WITH RESPECT TO SUCH TRANSFER, A
TRANSFER MEETING THE REQUIREMENTS OF RULE 144 OF THE SECURITIES ACT OF 1933, OR (IF REASONABLY REQUIRED BY COMPANY) AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY SUCH TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 

Company need not enter into its stock records a transfer of Warrant Shares unless the conditions specified in the foregoing legend are
satisfied. Company may also instruct its transfer agent not to allow the transfer of any of the Warrant Shares unless the conditions specified in the foregoing legend are satisfied. 

  
 5 

 (b) Removal of Legend and Transfer Restrictions. The legend relating to the Act
endorsed on a certificate pursuant to paragraph 5(a) of this Warrant shall be removed and Company shall issue a certificate without such legend to Holder if (i) the Securities are registered under the Act and a prospectus meeting the
requirements of Section 10 of the Act is available or (ii) Holder provides to Company an opinion of counsel for Holder reasonably satisfactory to Company, a no-action letter or interpretive opinion
of the staff of the Securities and Exchange Commission (“SEC”) reasonably satisfactory to Company, or other evidence reasonably satisfactory to Company, to the effect that public sale, transfer or assignment of the Securities may be made
without registration and without compliance with any restriction such as Rule 144. 
 6. Transfers of Warrant. In connection with any transfer by
Holder of this Warrant, Company may require the transferee to provide Company with the written representations and warranties set forth in Section 4(a) of this Warrant, may require that the transferee agree to be bound by the provisions of
Section 18 of this Warrant, and may require a legal opinion, in form and substance—satisfactory to Company and its counsel, stating that such transfer is exempt from the registration and prospectus delivery requirements of the Act;
provided, that Company shall not require an opinion of counsel if the transfer is to an affiliate of Holder. Following any transfer of this Warrant, at the request of either Company or the transferee, the transferee shall surrender this
Warrant to Company in exchange for a new warrant of like tenor and date, executed by Company. Upon any partial transfer, Company will also execute and deliver to Holder a new warrant of like tenor with respect to the portion of this Warrant not so
transferred. Subject to the foregoing, this Warrant is transferable on the books of Company at its principal office by the registered Holder hereof upon surrender of this Warrant properly endorsed. Holder shall not have any right to transfer any
portion of this Warrant to any direct competitor of Company. 
 7. Adjustment for Certain Events. The number and kind of securities purchasable upon
the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: 

(a) Reclassification or Merger. In case of (i) any reclassification or change of securities of the class issuable upon exercise of
this Warrant (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a subdivision or combination), (ii) any merger of Company with or into another corporation (other than a merger
with another corporation in which Company is the acquiring and the surviving corporation and which does not result in any reclassification or change of outstanding securities issuable upon exercise of this Warrant), or (iii) any sale of all or
substantially all of the assets of Company, Company, or such successor or purchasing corporation, as the case may be, shall duly execute and deliver to Holder a new Warrant (in form and substance satisfactory to Holder of this Warrant), or Company
shall make appropriate provision without the issuance of a new Warrant, so that Holder shall have the right to receive, at a total purchase price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, and in lieu of
the Warrant Shares theretofore issuable upon exercise or conversion of this Warrant, the kind and amount of shares of stock, other securities, money and property receivable upon such reclassification, change, merger or sale by a holder of the number
of shares of Preferred Stock then purchasable under this Warrant. Any new Warrant shall provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 7. The provisions of this
subparagraph (a) shall similarly apply to successive reclassifications, changes, mergers and transfers. 
 (b) Subdivision or
Combination of Shares. If Company at any time while this Warrant remains outstanding and unexpired shall subdivide or combine its outstanding shares of Preferred Stock, the Warrant Price shall be proportionately decreased and the number of
Warrant Shares issuable hereunder shall be proportionately increased in the case of a subdivision and the Warrant Price shall be proportionately increased and the number of Warrant Shares issuable hereunder shall be proportionately decreased in the
case of a combination. 
 (c) Stock Dividends and Other Distributions. If Company at any time while this Warrant is outstanding and
unexpired shall (i) pay a dividend with respect to Preferred Stock payable in Preferred Stock, then the Warrant Price shall be adjusted, from and after the date of determination of shareholders entitled to receive such dividend or distribution,
to that price determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to
such dividend or distribution, and (B) the 

  
 6 

 
denominator of which shall be the total number of shares of Preferred Stock outstanding immediately after such dividend or distribution; or (ii) make any other distribution with respect to
Preferred Stock (except any distribution specifically provided for in Sections 7(a) and 7(b)), then, in each such case, provision shall be made by Company such that Holder shall receive upon exercise of this Warrant a proportionate share of any such
dividend or distribution as though it were Holder of the Warrant Shares as of the record date fixed for the determination of the shareholders of Company entitled to receive such dividend or distribution. 

(d) Adjustment of Number of Shares. Upon each adjustment in the Warrant Price, the number of Warrant Shares purchasable hereunder shall
be adjusted, to the nearest whole share, to the product obtained by multiplying the number of Warrant Shares purchasable immediately prior to such adjustment in the Warrant Price by a fraction, the numerator of which shall be the Warrant Price
immediately prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter. 
 (e) Adjustment for
Dilutive Issuance. The Warrant Price and the number of Warrant Shares issuable upon exercise of this Warrant or, if the Warrant Shares are Preferred Stock, the number of shares of Common Stock issuable upon conversion of the Warrant Shares shall
be subject to adjustment from time to time in the manner set forth in Company’s Certificate of Incorporation as if the Warrant Shares were issued and outstanding on and as of the date of any such required adjustment. The provisions set forth
for the Warrant Shares in Company’s Certificate of Incorporation relating to the above in effect as of the date hereof may not be amended, modified or waived, without the prior written consent of Holder unless such amendment, modification or
waiver affects the rights associated with the Warrant Shares in the same manner as such amendment, modification or waiver affects the rights associated with all other shares of the same series and class as the Warrant Shares. 

(f) Adjustment for Pay-to-Play Transaction. In the event
that the Company’s Certificate of Incorporation provides, or is amended to so provide, for the amendment or modification of the rights, preferences or privileges of the Preferred Stock, or the reclassification,- conversion or exchange of the
Preferred Stock, on account of the failure of a holder of the Preferred Stock to participate in an equity financing transaction (a “Pay-to-Play Provision”),
such Pay-to-Play Provision shall not apply to the Holder with respect to any portion of this Warrant not yet converted or exercised and any portion of this Warrant not
yet converted or exercised shall remain exercisable for the same number and type of shares of equity securities for which it was exercisable immediately prior to such equity financing transaction. 

8. Notice of Adjustments: Redemption. Whenever any Warrant Price or the kind or number of securities issuable under this Warrant shall be adjusted
pursuant to Section 7 hereof, Company shall prepare a certificate signed by an officer of Company setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was
calculated, and the Warrant Price and number or kind of shares issuable upon exercise of this Warrant after giving effect to such adjustment, and within thirty (30) days of such adjustment shall cause copies of such certificate to be delivered
to Holder in accordance with Section 18 hereof. 
 9. Financial and Other Reports. 

(a) Financial Statements. From time to time up to the earlier of the Expiration Date or the complete exercise or conversion of this
Warrant, Company shall furnish to Holder, (i) as soon as available and in any event within 30 days after the end of each fiscal month, unaudited consolidated (and if available, consolidating) balance sheets, statements of income or operations
and cash flow statements of Company and its Subsidiaries as of the end of such fiscal month and that portion of the fiscal year ending as of the close of such fiscal month, in a form reasonably acceptable to Holder and certified by Company’s
president, chief executive officer or chief financial officer and (ii) as soon as available and in any event within one hundred and twenty (120) days after the end of each fiscal year, audited consolidated (and if available, consolidating)
balance sheets, statements of income or operations and cash flow statements of Company and its Subsidiaries as of the end of such fiscal year, together with a report of an independent certified public accounting firm reasonably acceptable to Holder,
which report shall contain an unqualified opinion stating that such audited financial statements fairly present in all material respects the financial position of Company and its Subsidiaries for the periods indicated therein in conformity with GAAP
applied on a basis consistent with prior years without qualification as to the scope of the audit or as to going concern and without any similar qualification. All such financial statements are to be prepared using GAAP (subject, in the case of
unaudited financial statements, to the absence of footnotes and normal year end audit adjustments). 

  
 7 

 (b) Capitalization Table. Within 30 days of the end of each calendar quarter, if the
Company is a private company, Company shall also deliver to Holder an updated capitalization table of Company in the form attached hereto as Annex A. 
 10.
Registration Rights. Upon request of Holder, Company shall use commercially reasonable efforts to grant to Holder piggyback registration rights for the Warrant Shares to the extent that such registration rights have been granted to holders of
the Preferred Stock, subject to any reasonable and customary requests of the Company, including agreement by Holder to be bound, as a “Holder” by that certain Sixth Amended and Restated Investors’ Rights Agreement, dated as of
February 7, 2014, by and among the Company and certain of the Company’s stockholders, as the same may be amended from time to time in accordance with its terms (the “Rights Agreement”). Such registration rights shall be on terms
no less favorable to Holder than the piggyback registration rights granted to holders of the Preferred Stock. 
 11. No Fractional Shares. No
fractional share of Preferred Stock will be issued in connection with any exercise or conversion hereunder, but in lieu of such fractional share Company shall make a cash payment therefor upon the basis of the Warrant Price then in effect. 

12. Charges, Taxes and Expenses. Issuance of certificates for shares of Preferred Stock upon the exercise or conversion of this Warrant shall be made
without charge to Holder for any United States or state of the United States documentary stamp tax or other incidental expense with respect to the issuance of such certificate, all of which taxes and expenses shall be paid by Company, and such
certificates shall be issued in the name of Holder. 
 13. No Shareholder Rights Until Exercise. Except as expressly provided herein, this Warrant
does not entitle Holder to any voting rights or other rights as a shareholder of Company prior to the exercise hereof. 
 14. Registry of Warrant.
Company shall maintain a registry showing the name and address of the registered Holder of this Warrant. This Warrant may be surrendered for exchange or exercise, in accordance with its terms, at such office or agency of Company, and Company and
Holder shall be entitled to rely in all respects, prior to written notice to the contrary, upon such registry. 
 15. Loss, Theft, Destruction or
Mutilation of Warrant. Upon receipt by Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft, or destruction, of indemnity reasonably satisfactory to it,
and, if mutilated, upon surrender and cancellation of this Warrant, Company will execute and deliver a new Warrant, having terms and conditions substantially identical to this Warrant, in lieu hereof. 

16. Miscellaneous. 
 (a) Issue Date.
The provisions of this Warrant shall be construed and shall be given effect in all respect as if it had been issued and delivered by Company on the date hereof. 

(b) Successors. This Warrant shall be binding upon any successors or assigns of Company. 

(c) Headings. The headings used in this Warrant are used for convenience only and are not to be considered in construing or interpreting
this Warrant. 
 (d) Saturdays, Sundays, Holidays. If the last or appointed day for the taking of any action or the expiration of any
right required or granted herein shall be a Saturday or a Sunday or shall be a legal holiday in the State of New York, then such action may be taken or such right may be exercised on the next succeeding day not a Saturday, Sunday or a legal holiday.

  
 8 

 17. No Impairment. Company will not, by amendment of its Certificate of Incorporation or any other
voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or
appropriate in order to protect the rights of Holder hereof against impairment; provided, however, that notwithstanding the foregoing, nothing in this Section 17 shall restrict or impair Company’s right to effect any changes
to the rights, preferences, privileges or restrictions associated with the Warrant Shares in the same manner as such rights, privileges or restrictions associated with the same series of stock as the Warrant Shares are changed or to authorize or
issue shares of Company’s capital stock that are on parity with, or senior to, the Warrant Shares with respect to liquidation, dividend, redemption and other rights. 

18. Market Stand-Off Agreement. Holder shall not sell, dispose, transfer, make any short sale, grant any option
for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, of any Common Stock (or other securities) of the Company held by Holder (other than those included in the registration), for a period of
time specified by the managing underwriter(s) (not to exceed one hundred eighty (180) days or such longer period that the Company shall reasonably request in order to accommodate regulatory restrictions on (x) the publication or other
distribution of research reports and (y) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(1)(4) or NYSE Rule 472(0)(4), as applicable, (or any successor rules or amendments
thereto) following the effective date of a registration statement for the Company’s initial public offering filed under the Act); provided that the restrictions of this Section 18 (i) shall apply only to the Company’s initial public
offering; (ii) shall not apply to transfers to Holder’s Affiliates provided that such Affiliates agree to be bound by this Section 18; (iii) shall not apply to transfers of Holder’s securities of the Company prior to the time the
initial public offering price range is first filed by the Company with the Securities and Exchange Commission in the preliminary prospectus; (iv) shall not apply to securities of the Company purchased in the initial public offering or in the
public market for the Company’s securities following the initial public offering; (v) shall only apply in the event that all officers and directors of the Company and holders of at least one percent (1%) of the Company’s voting
securities (each, an “Other Holder’’) are subject to restrictions regarding their Company securities no less restrictive than those contained herein; and (vi) in the event that any Other Holder is released, in whole or in part,
from such agreement or restriction referred to in clause (v) above (whether or not such release is contemplated at the time of the offering) or if any such agreement or restrictions are terminated, then Holder shall be concurrently released on
a pro rata basis (based on the number of shares being so released and the total number of shares held by such person). In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the shares of Common
Stock (or other securities) subject to the foregoing restriction until the end of such period specified above. 
 19. Addresses. All notices or other
communications given in connection with this Warrant shall be in writing, shall be addressed to the parties at their respective addresses set forth below (unless and until a different address may be specified in a written notice to the other party
delivered in accordance with this Section 18), and shall be deemed given (a) on the date of receipt if delivered by hand, (b) on the next business day after being sent by a nationally-recognized overnight courier, or (c) on the
fourth business day after being sent by registered or certified mail, return receipt requested and postage prepaid. 
  

					
		 	If to Company:	  	Cardiva Medical, Inc.
		 		  	888 W. Maude Ave.,
		 		  	Sunnyvale, CA 94085
		 		  	Attn: Chief Executive Officer
		
		 	With copies, which shall not constitute notice, to:
			
		 		  	Michael W. Hall
		 		  	Latham & Watkins, LLP
		 		  	140 Scott Drive, Menlo Park, CA 94025
			
		 	If to Holder:	  	
			
		 		  	East West Bank
		 		  	2350 Mission College Blvd., Suite 988
		 		  	Santa Clara, CA 95054

  
 9 

 20. WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS WARRANT OR THE WARRANT SHARES. 

21. GOVERNING LAW. THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. 

[Remainder of page intentionally left blank] 

  
 10 

 IN WITNESS WHEREOF, Company has caused this Warrant to be executed by its officer thereunto
duly authorized. 
 CARDIVA MEDICAL, INC. 
  

			
	By:	 	      

	Name:
	Title:

 NOTICE OF EXERCISE 

To: 
 Cardiva Medical, Inc. 

888 W. Maude Ave., 
 Sunnyvale, CA 94085 

Attn: Chief Executive Officer 
  

	1.	 The undersigned Warrantholder (“Holder’’) elects to acquire shares of the Series 3 Preferred
Stock (the “Preferred Stock”) of Cardiva Medical, Inc. (the “Company”), pursuant to the terms of the Stock Purchase Warrant dated July 24, 2014 (the “Warrant”). 

 

	2.	 Holder exercises its rights under the Warrant as set forth below: 

 

			
	(             )	  	 Holder elects to purchase ____________ shares of Preferred Stock as provided in Section 3(a) and tenders herewith
a check in the amount of $____________ as payment of the purchase price.

		
	(             )	  	 Holder elects to convert the purchase rights into shares of Preferred Stock as provided in Section 3(b) of the
Warrant.

  

	3.	 Holder surrenders the Warrant with this Notice of Exercise. 

Holder hereby restates each of the representations set forth in Section 4(a) of the Warrant as of the date hereof. 

Please issue a certificate representing the shares of the Preferred Stock in the name of Holder or in such other name as is specified below: 

 

					
		  	Name:	  	                                      
          
			
		  	Address:	  	                                      
          
			
		  	Taxpayer I.D.:	  	                                      
          

  

			
	[NAME OF HOLDER]
		
	By:	 	  

		 	Name:                                     
                                         
          
		 	Title: Duly Authorized Signatory
	
	Date: ____________20__

 ANNEX A 

CAPITALIZATION TABLE 
 [SEE
ATTACHED] 

 Cardiva Medical, Inc. 

Fully Diluted Capitalization Table - Summary 

As of 7/22/2014 
  

									
	 	  	CSE
Shares*	 	  	Total
Fully Diluted
Shares	 
	 COMMON STOCK (Authorized: 60,000,000)
	  				  			
	 Issued and Outstanding
	  	 	2,158,188	 	  	 	2,158,188	 
	 PREFERRED STOCK (Authorized: 40,000,000)
	  				  			
	 SERIES A Preferred Stock (Authorized: 0)
	  	 	0	 	  			
	 SERIES B Preferred Stock (Authorized: 0)
	  	 	0	 	  			
	 SERIES C Preferred Stock (Authorized: 0)
	  	 	0	 	  			
	 SERIES D Preferred Stock (Authorized: 0)
	  	 	0	 	  			
	 SERIES I Preferred Stock (Authorized: 0)
	  	 	0	 	  			
	 SERIES IA Preferred Stock (Authorized: 0)
	  	 	0	 	  			
	 SERIES 1B Preferred Stock (Authorized: 0)
	  	 	0	 	  			
	 SERIES 2 Preferred Stock (Authorized: 0)
	  	 	0	 	  			
	 SERIES 3 Preferred Stock (Authorized: 40,000,000)
	  	 	22,921,201	 	  	 	22,921,201	 
		  	  
	  
	 	  			
	 WARRANTS
	  				  			
	 COMMON Stock
	  	 	448,895	 	  			
	 SERIES 3 Preferred Stock
	  	 	23,689	 	  	 	472,584	 
		  	  
	  
	 	  			
	 2002 SOP (Reserved: 32,092)
	  				  			
	 Shares Issuable Under Plan:
	  				  			
	 Options and/or SPRs Issued and Outstanding
	  	 	395	 	  			
	 Options and/or SPRs Committed for Issuance
	  	 	0	 	  			
	 Shares Remaining for Issuance Under Plan
	  	 	0	 	  	 	395	 
		  	  
	  
	 	  			
	 Reserved in Plan
	  	 	32,092	 	  			
	 Options and/or SPRs Exercised
	  	 	(33,069	) 	  			
	 Repurchases
	  	 	1,518	 	  			
	 2014 EIP (Reserved: 4,689,985)
	  				  			
	 Shares Issuable Under Plan:
	  				  			
	 Options and/or SPRs Issued and Outstanding
	  	 	456,875	 	  			
	 Options and/or SPRs Committed for Issuance
	  	 	0	 	  			
	 Shares Remaining for Issuance Under Plan
	  	 	2,081,235	 	  	 	2,538,110	 
		  	  
	  
	 	  			
	 Reserved in Plan
	  	 	4,689,985	 	  			
	 Options and/or SPRs Exercised
	  	 	(2,151,875	) 	  			
		  				  	  
	  
	 
	 Total shares issued & outstanding, including shares committed for issuance and
employee reserves, assuming conversion of all convertible securities and exercise of all outstanding options
	  				  	 	28,090,478	 
		  				  	  
	  
	 

  

 Cardiva Medical, Inc. 

Fully Diluted Capitalization Table - Summary 

As of 7/22/2014 
  

 Footnote(s): 
  

			
	CSE Shares*	  	Common Stock Equivalent (CSE) shares reflects the Common Stock issuable for the security type (option, stock, warrant, CPN) after the appropriate conversion ratio is applied with regard to parameters set for aggregation/rounding for
each class/series. Reserved reflects Current Reserved Amount; if the option plan has shares pouring in from another plan, this number will change as new shares are poured in from the old plan.

 Cardiva Medical, Inc. 

Fully Diluted Capitalization Table - Summary 

As of 7/22/2014 
  

 Fully-Diluted Ownership 

 

									
	 	  	Number of Shares	 	  	Percent(%)	 
	 Common Stock
	  	 	2,158,188	 	  	 	7.68	 
	 SERIES A Preferred Stock
	  	 	0	 	  	 	0.00	 
	 SERIES B Preferred Stock
	  	 	0	 	  	 	0.00	 
	 SERIES C Preferred Stock
	  	 	0	 	  	 	0.00	 
	 SERIES D Preferred Stock
	  	 	0	 	  	 	0.00	 
	 SERIES I Preferred Stock
	  	 	0	 	  	 	0.00	 
	 SERIES IA Preferred Stock
	  	 	0	 	  	 	0.00	 
	 SERIES 1B Preferred Stock
	  	 	0	 	  	 	0.00	 
	 SERIES 2 Preferred Stock
	  	 	0	 	  	 	0.00	 
	 SERIES 3 Preferred Stock
	  	 	22,921,201	 	  	 	81.60	 
	 COMMON Stock Warrants
	  	 	448,895	 	  	 	1.60	 
	 SERIES 3 Preferred Stock Warrants
	  	 	23,689	 	  	 	0.08	 
	 Options and/or SPRs issued and outstanding under plan - 2002 SOP
	  	 	395	 	  	 	0.00	 
	 Committed for Issuance - 2002 SOP
	  	 	0	 	  	 	0.00	 
	 Unissued Reserve - 2002 SOP
	  	 	0	 	  	 	0.00	 
	 Options and/or SPRs issued and outstanding under plan-2014 EIP
	  	 	456,875	 	  	 	1.63	 
	 Committed for Issuance - 2014 EIP
	  	 	0	 	  	 	0.00	 
	 Unissued Reserve - 2014 EIP
	  	 	2,081,235	 	  	 	7.41	 
		  	  
	  
	 	  	  
	  
	 
	 TOTAL
	  	 	28,090,478	 	  	 	100.00	 

 The following Stock Split(s) have occurred: 

04/25/2011    1:50 Reverse 
 As applicable,
the shares and prices have been restated accordingly.EX-10.13

 Exhibit 10.13 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE
STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO
RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT TO PURCHASE
STOCK 
  

			
	 Corporation:
	  	Cardiva Medical, Inc., a Delaware corporation
	 Number of Shares:
	  	23,689 (Subject to Section 1.5)
	 Class of Stock:
	  	Series 3 Preferred Stock
	 Warrant Price:
	  	$1.25 per share
	 Issue Date:
	  	June 26, 2014
	 Expiration Date:
	  	June 26, 2022 (Subject to Section 5.1)

 THIS WARRANT TO PURCHASE STOCK (THIS “WARRANT”) CERTIFIES THAT, for good and valuable consideration,
the receipt of which is hereby acknowledged, COMERICA BANK, a Texas banking association, or its assignee (“Holder”), is entitled to purchase the number of fully paid and nonassessable shares of Series 3 Preferred Stock (the
“Shares”) of CARDIVA MEDICAL, INC. (the “Company”) at the Warrant Price, all as set forth above and as adjusted pursuant to the terms of this Warrant, subject to the provisions and upon the terms and conditions set forth in this
Warrant. 
 ARTICLE 1 

EXERCISE 
 1.1 Method of
Exercise. Holder may exercise this Warrant from time to time for all or any part of the unexercised Shares by delivering a duly executed Notice of Exercise in substantially the form attached as Appendix I to the principal office of the Company
(or such other appropriate location as Holder is so instructed by the Company). Holder shall also deliver to the Company a check, wire transfer (to an account designated by the Company) or other form of payment acceptable to the Company for the
aggregate Warrant Price for the Shares being purchased. Notwithstanding any other provision hereof, if an exercise of any portion of this Warrant is to be made in connection with a public offering or an Acquisition (as defined below), such exercise
may at the election of the Holder be conditioned upon the consummation of such transaction, in which case such exercise shall not be deemed to be effective until immediately prior to the closing of such transaction. 

1.2 Delivery of Certificate and New Warrant. Within thirty (30) days after Holder exercises this Warrant and the Company receives
payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised and has not expired, a new warrant representing the Shares not so acquired. 

1.3 Replacement of Warrants. In the case of loss, theft or destruction of this Warrant, upon delivery of an indemnity agreement
reasonably satisfactory in form and amount to the Company or, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor.

 1.4 Acquisition of the Company. 

1.4.1 “Acquisition.” For the purpose of this Warrant, “Acquisition” means (a) any sale,
license, or other disposition of all or substantially all of the assets (including intellectual property) of the Company, or (b) any reorganization, consolidation, merger, sale of the voting securities of the Company or other transaction or
series of related transactions where the holders of the Company’s securities before the 
  

 transaction or series of related transactions beneficially own less than fifty percent (50%)
of the outstanding voting securities of the surviving entity after the transaction or series of related transactions (other than in connection with a bona fide sale or issuance of securities of the Company for capital raising purposes the primary
purpose of which is to fund the Company’s operations). 
 1.4.2 Treatment of Warrant in the Event of an
Acquisition. The Company shall give Holder written notice at least twenty (20) days prior to the closing of any proposed Acquisition. The Company will use commercially reasonable efforts to cause (i) the acquirer of the Company,
(ii) successor or surviving entity or (iii) parent entity in an Acquisition (the “Acquirer”) to assume this Warrant as a part of the Acquisition. 

(a) If the Acquirer assumes this Warrant, then this Warrant shall be exercisable for the same securities, cash, and property as
would be payable for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price shall be adjusted accordingly, and
the Warrant Price and number and class of Shares shall continue to be subject to adjustment from time to time in accordance with the provisions hereof. 

(b) If the Acquirer refuses to assume this Warrant in connection with the Acquisition, the Company shall give Holder an
additional written notice at least ten (10) days prior to the closing of the Acquisition of such fact. In such event, notwithstanding any other provision of this Warrant to the contrary, Holder may immediately exercise this Warrant in the
manner specified in this Warrant with such exercise effective immediately prior to closing of the Acquisition. If Holder elects not to exercise this Warrant, then this Warrant will terminate immediately prior to the closing of the Acquisition.
Notwithstanding any other provision of this Warrant to the contrary if the Acquirer refuses to assume this Warrant in connection with such Acquisition, other than in connection with an Excluded Acquisition (as defined below), then effective as of
the date that is ten (10) days prior to the closing of such Acquisition, the Holder shall have the option to put this Warrant to the Company for a per Share amount equal to the difference between the Acquisition consideration payable for one
Share and the Warrant Price. As used herein, an “ Excluded Acquisition” means, an Acquisition where the consideration that the holders of the Shares are entitled to receive on account of the Shares consists entirely of cash and/or shares
of common stock that are publicly traded on a national exchange and where the shares, if any, receivable by the Holder of this Warrant were the Holder to exercise this Warrant in full immediately prior to the closing of such Acquisition may be
publicly re-sold by the Holder in their entirety within the three (3) months following such closing pursuant to Rule 144 or an effective registration statement under the Act. 

1.5 Adjustment in Number of Shares Purchasable. If any amounts are outstanding the Term Loan D (as defined in the Amended and Restated
Loan and Security Agreement dated as of July 23, 2013 between the Company and Comerica Bank, as it may be amended, replaced or supplemented from time to time, the “Loan Agreement”) on August 25, 2014, the “Number of
Shares” set forth on page 1 of this Warrant shall automatically be increased by an additional 47,378 shares. The Warrant Price shall not change as a result of the increased number of Shares issuable under this Warrant pursuant to this
Section 1.5. 
 ARTICLE 2 

ADJUSTMENTS TO THE SHARES 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on its Series 3 Preferred Stock payable in common stock,
or other securities, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares of record as
of the date the dividend occurred. If the Company subdivides, splits or multiplies the outstanding shares of Series 3 Preferred Stock by reclassification or otherwise into a greater number of Shares, the number of Shares purchasable hereunder shall
be proportionally increased and the Warrant Price shall be proportionally decreased. 

  
 2 

 2.2 Reclassification, Exchange or Substitution. Upon any reclassification, exchange,
substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and
kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other event. Such an event shall include any automatic conversion
of the outstanding or issuable securities of the Company of the same class or series as the Shares to common stock pursuant to the terms of the Company’s Amended and Restated Certificate of Incorporation. The Company or its successor shall
promptly issue to Holder a new warrant for such new securities or other property. The new warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including,
without limitation, adjustments to the Warrant Price, the number of securities or property issuable upon exercise of the new warrant and expiration date. The provisions of this Section 2.2 shall similarly apply to successive reclassifications,
exchanges, substitutions, or other events. 
 2.3 Adjustments for Combinations, Etc. If the outstanding Shares are combined or
consolidated, by reclassification, reverse split or otherwise, into a lesser number of Shares, the number of Shares purchasable hereunder shall be proportionally decreased and the Warrant Price shall be proportionately increased. 

2.4 Adjustments for Diluting Issuances. In the event of the issuance (a “Diluting Issuance”) by the Company, after the Issue
Date of this Warrant, of securities at a price per share less than the Warrant Price, then the number of shares of common stock issuable upon conversion of the Shares shall be adjusted in accordance with those provisions of the Company’s
Amended and Restated Articles of Incorporation, a copy of which is attached hereto as Exhibit A, which apply to Diluting Issuances as if the Shares were outstanding on the date of such Diluting Issuance. The provisions set forth for the
Shares in the Company’s Certificate of Incorporation relating to the above in effect as of the Issue Date may not be amended, modified or waived, without the prior written consent of Holder unless such amendment, modification or waiver affects
the rights associated with the Shares in the same manner as such amendment, modification or waiver affects the rights associated with all other shares of the same series and class as the Shares granted to the Holder Under no circumstances shall the
aggregate Warrant Price payable by the Holder upon exercise of this Warrant increase as a result of any adjustment arising from a Diluting Issuance. 

2.5 No Impairment. The Company shall not, by amendment of its Amended and Restated Certificate of Incorporation or Bylaws or through a
reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this
Warrant by the Company, but shall at all times in good faith assist in carrying out all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s rights under this Article 2 against
impairment. 
 2.6 Certificate as to Adjustments. Upon each adjustment of the Warrant Price or number of Shares, the Company at its
expense shall promptly compute such adjustment, and furnish Holder with a certificate signed by its Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request,
furnish Holder a certificate setting forth the Warrant Price and number of Shares in effect upon the date thereof and the series of adjustments leading to such Warrant Price and number of Shares. 

2.7 Fractional Shares. No fractional Shares shall be issuable upon exercise of this Warrant and the Number of Shares to be issued shall
be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise of this Warrant, the Company shall eliminate such fractional share interest by paying Holder an amount in cash computed by multiplying the fractional
interest by the fair market value, as determined by the Company’s Board of Directors, of a full Share. 
 ARTICLE 3 

REPRESENTATIONS AND COVENANTS OF THE COMPANY 

3.1 Representations and Warranties. The Company hereby represents and warrants to, and agrees with, the Holder as follows: 

3.1.1 The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which
Series 3 Preferred Stock was last sold for cash consideration prior to the Issue Date. 

  
 3 

 3.1.2 This Warrant is and any Warrant issued in substitution for or
replacement of this Warrant shall be, upon issuance, duly authorized and validly issued. All Shares which may be issued upon the exercise of the purchase right represented by this Warrant, and all securities, if any, issuable upon conversion of the
Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws.

 3.1.3 The Company’s capitalization table delivered to Holder as of the Issue Date is true and complete as of the
Issue Date. 
 3.2 Notice of Certain Events. If the Company proposes at any time (a) to declare any dividend or distribution upon
its stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class
or series or other rights; (c) to effect any reclassification or recapitalization of stock; or (d) to merge or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to
liquidate, dissolve or wind up, then, in connection with each such event, the Company shall give Holder (1) at least twenty (20) days prior written notice of the date on which a record will be taken for such dividend, distribution, or
subscription rights (and specifying the date on which the holders of stock will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above; and (2) in the case of the matters
referred to in (c) and (d) above at least twenty (20) days prior written notice of the date when the same will take place (and specifying the date on which the holders of stock will be entitled to exchange their stock for securities or
other property deliverable upon the occurrence of such event). Upon request, the Company shall provide Holder with such information reasonably necessary for Holder to evaluate its rights as a holder of this Warrant or Warrant Shares in the case of
matters referred to (a), (b), (c) and (d) herein above. 
 3.3 Information Rights. So long as the Holder holds this Warrant
and/or any of the Shares, the Company shall deliver to the Holder (a) promptly after mailing, copies of all communications, information and/or communiqués to the current holders of the Shares, (b) within ninety (90) days after
the end of each fiscal year of the Company, the annual audited financial statements of the Company certified by independent public accountants of recognized standing and (c) within thirty (30) days after the end of each month, the
Company’s monthly, unaudited financial statements subject to normal year-end audit adjustments. In addition, and without limiting the generality of the foregoing, so long as the Holder holds this Warrant
and/or any of the Shares, the Company shall afford to the Holder the same access to information concerning the Company and its business and financial condition as would be afforded to a holder of the class of Shares under applicable state law and/or
any agreement with any holder of the class of Shares. The information rights set forth in this Article 3.3 shall terminate and be of no further force or effect upon the closing of the Company’s initial public offering of Common Stock of the
Company pursuant to an effective registration statement filed under the Act. 
 3.4 Registration Under the Act. The Company agrees
that the Shares or, if the Shares are convertible into common stock of the Company, such common stock, shall be deemed “Registrable Securities” or otherwise entitled to “piggy back” registration rights for registrations initiated
by either the Company or a stockholder in accordance with the terms of the that certain Amended and Restated Investors Rights Agreement between the Company and its investor dated as of February 7, 2014, as amended from time to time (the
“Rights Agreement”), a copy of which is attached hereto as Exhibit B. Holder agrees that upon exercise of this Warrant it shall have all of the rights and be bound by all of the terms and conditions of the Rights Agreement, except that
transfers from any Holder to an affiliate of such Holder shall be deemed a permitted transfer under Section 2.8(b) of the Rights Agreement. The Company agrees that no amendments will be made to the Rights Agreement which would have an adverse
impact on Holder’s registration rights thereunder unless such amendment affects the rights associated with all other holders of Shares in the same manner as such amendment affects Holder. 

  
 4 

 ARTICLE 4 

INVESTMENT REPRESENTATIONS AND WARRANTIES 

With respect to the acquisition of this Warrant and any of the Shares, Holder hereby represents and warrants to, and agrees with, the Company
as follows: 
 4.1 Purchase Entirely for Own Account. This Warrant is issued to Holder in reliance upon Holder’s representation
to the Company that this Warrant and the Shares (and the shares of Common Stock issuable upon conversion of the Shares) will be acquired for investment for Holder’s own account, not as a nominee or agent, and not with a view to the resale or
distribution of any part thereof other than to a Bank Affiliate (as defined below), and that Holder has no present intention of selling, granting any participation in, or otherwise distributing the same other than to a Bank Affiliate. By executing
this Warrant, Holder further represents that Holder does not have any contract, undertaking, agreement or arrangement with any person, other than a Bank Affiliate, to sell, transfer or grant participations to such person or to any third person with
respect to any of the Shares. 
 4.2 Reliance upon Holder’s Representations. Holder understands that this Warrant and the Shares
are not registered under the Act on the ground that the issuance of such securities is exempt from registration under the Act, and that the Company’s reliance on such exemption is predicated on Holder’s representations set forth herein.

 4.3 Accredited Investor Status. Holder represents to the Company that Holder is an Accredited Investor (as defined in the Act).

 4.4 Restricted Securities. Holder understands that this Warrant and the Shares are “restricted securities” under the
federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such federal securities laws and applicable regulations such securities may be resold without registration
under the Act only in certain limited circumstances. 
 ARTICLE 5 

MISCELLANEOUS 
 5.1
Term; Exercise Upon Expiration. This Warrant is exercisable in whole or in part, at any time and from time to time on or before the Expiration Date set forth above; provided, however, that if the Company completes its initial public offering
within the one-year period immediately prior to the Expiration Date, the Expiration Date shall automatically be extended until the first anniversary of the effective date of the Company’s initial public
offering. The Company shall give Holder written notice of Holder’s right to exercise this Warrant not less than ninety (90) days before the Expiration Date. If the notice is not so given, the Expiration Date shall automatically be extended
until ninety (90) days after the date the Company delivers such notice to Holder. The Company agrees that Holder may terminate this Warrant, upon notice to the Company, at any time in its sole discretion. 

5.2 Legends. This Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any)
shall be imprinted with legends as set forth in the Rights Agreement, including a legend in substantially the following form: 
 THIS WARRANT
AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE
OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS. 
 5.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this
Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and
the transferee. The Company shall not require Comerica Bank (“Bank”) or a Bank Affiliate (as defined herein) to provide an opinion of counsel or investment representation letter if the transfer is to Bank’s parent company, Comerica
Incorporated (“Comerica”), or any other affiliate of Bank (“Bank Affiliate”). 

  
 5 

 5.4 Transfer Procedure. After receipt of the executed Warrant, Bank will transfer all
of this Warrant to Comerica Ventures Incorporated, a non-banking subsidiary of Comerica and a Bank Affiliate (“Ventures”). Subject to the provisions of Article 5.3, Holder may transfer all or part of
this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company notice of the portion of this Warrant being transferred setting forth
the name, address and taxpayer identification number of the transferee and surrendering this Warrant to the Company for reissuance to the transferee(s) (and Holder, if applicable); provided, however, that Holder may transfer all or part of this
Warrant to its affiliates, including, without limitation, Ventures, at any time without notice or the delivery of any other instrument to the Company, and such affiliate shall then be (a) entitled to all the rights of Holder under this Warrant
and any related agreements and (b) bound by the provisions of the Rights Agreement, except that such transfer shall be deemed a permitted transfer under Section 2.8(b) of the Rights Agreement, and the Company shall cooperate fully in
ensuring that any stock issued upon exercise of this Warrant is issued in the name of the affiliate that exercises this Warrant. The terms and conditions of this Warrant shall inure to the benefit of, and be binding upon, the Company and the holders
hereof and their respective permitted successors and assigns. 
 5.5 Notices. All notices and other communications from the Company to
the Holder, or vice versa, shall be deemed delivered and effective when: (i) given personally or mailed by first-class registered or certified mail, postage prepaid, or sent via a nationally recognized overnight courier service (such as, but
not limited to, Federal Express, DHL or UPS), fee prepaid, or (ii) on the date sent by email or facsimile if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient.
Such communications must be sent to the respective parties at the address or facsimile number as may have been furnished to the Company or the Holder, as the case may be, in writing by the Company or such Holder from time to time. Effective upon the
receipt of executed Warrant and initial transfer described in Article 5.4 above, all notices to the Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 

Comerica Ventures Incorporated 

Attn: Warrant Administrator 

1717 Main Street, 5th Floor, MC 6406 

Dallas, Texas 75201 
 Facsimile
No. [Intentionally omitted] 
 All notices to the Company shall be addressed as follows: 

Cardiva Medical, Inc. 
 Attn:
Chief Financial Officer 
 888 W. Maude Avenue 

Sunnyvale, California 94085 
 5.6
Amendments; Waiver. This Warrant and any term hereof may be amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by the Company or the Holder of any of the provisions hereof shall be effective
unless explicitly set forth in writing and signed by the party so waiving. No failure to exercise, or delay in exercising, any rights, remedy, power or privilege arising from this Warrant shall operate or be construed as a waiver thereof, nor shall
any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. 

5.7 Cumulative Remedies. The rights and remedies provided in this Warrant are cumulative and are not exclusive of, and are in addition
and not in substitution for, any other rights or remedies available at law, in equity or otherwise. 
 5.8 Attorneys’ Fees. In
the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable
attorneys’ fees. 

  
 6 

 5.9 No Strict Construction. This Warrant shall be construed without regard to any
presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. 

5.10 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without
giving effect to its principles regarding conflicts of law. 
 5.11 Counterparts. This Warrant may be executed in counterparts, all of
which taken together shall constitute one and the same instrument. 
  

			
	CARDIVA MEDICAL, INC.
		
	By:	 	   /s/ Mac Farnsworth

	
	Name: Mac Farnsworth
	
	Title: CFO
	
	COMERICA BANK, a Texas banking association
		
	By:	 	   /s/ Paul Gerling

	
	Name: Paul Gerling
	
	Title: Senior Vice President

  
 7 

 APPENDIX I 

NOTICE OF EXERCISE 

1. The undersigned hereby elects to purchase
                 shares of the Series 3 Preferred Stock of Cardiva Medical, Inc. pursuant to the terms of the attached Warrant, and tenders
herewith payment of the purchase price of such shares in full. 
 2. Please issue a certificate or certificates representing said shares in
the name of the undersigned or in such other name as is specified below: 
 Comerica Ventures Incorporated 

Attn: Warrant Administrator 
 1717
Main Street, 5th Floor, MC 6406 
 Dallas, Texas 75201 

Facsimile No. [Intentionally omitted] 

3. The undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a
view toward the resale or distribution thereof except in compliance with applicable securities laws. 
  

	
	COMERICA VENTURES INCORPORATED or Assignee
	
	  

	(Signature)
	
	  

	(Name and Title)
	
	  

	(Date)

  

  
 APPENDIX I 

 Exhibit A 

Anti-Dilution Provisions 

Certificate of Incorporation (including all amendments thereto) 

ATTACHED HERETO 
  

  
 EXHIBIT A 

 Exhibit B 

Registration Rights 
 Rights
Agreement (including all amendments thereto) 
 - ATTACHED HERETO 
  

  
 EXHIBIT B

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]